The Prognostic Significance of Measurable (“Minimal”) Residual Disease in Acute Myeloid Leukemia

被引：0
|
作者：
Francesco Buccisano
Christopher S. Hourigan
Roland B. Walter
机构：
[1] University Tor Vergata,Department of Biomedicine and Prevention, Hematology
[2] National Institutes of Health,Myeloid Malignancies Section, Hematology Branch, National Heart, Lung, and Blood Institute
[3] Fred Hutchinson Cancer Research Center,Clinical Research Division
[4] University of Washington,Department of Medicine, Division of Hematology
[5] University of Washington,Department of Epidemiology
来源：
Current Hematologic Malignancy Reports | 2017年 / 12卷
关键词：
Acute myeloid leukemia; Flow cytometry; Minimal residual disease; Next-generation sequencing; Polymerase chain reaction; Prognostication;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：547 / 556
页数：9
相关论文
共 50 条
  • [41] Monitoring of minimal residual disease in acute myeloid leukemia
    Buccisano, Francesco
    Maurillo, Luca
    Spagnoli, Alessandra
    Del Principe, Maria Ilaria
    Ceresoli, Eleonora
    Lo Coco, Francesco
    Arcese, William
    Amadori, Sergio
    Venditti, Adriano
    CURRENT OPINION IN ONCOLOGY, 2009, 21 (06) : 582 - 588
  • [42] Prognostic stratification and minimal residual disease assessment in Acute Myeloid Leukemia by molecular techniques
    Kakkas, I.
    ARCHIVES OF HELLENIC MEDICINE, 2013, 30 (05): : 566 - 573
  • [43] The detection and significance of minimal residual disease in chronic myeloid leukemia
    Radich, JP
    MEDICINA-BUENOS AIRES, 2000, 60 : 66 - 70
  • [44] Identifying leukemia-associated immunophenotype-based individualized minimal residual disease in acute myeloid leukemia and its prognostic significance
    Sui, Jing-Ni
    Chen, Qiu-Sheng
    Zhang, Yun-Xiang
    Sheng, Yan
    Wu, Jing
    Li, Jun-Min
    Weng, Xiang-Qin
    Chen, Bing
    AMERICAN JOURNAL OF HEMATOLOGY, 2019, 94 (05) : 528 - 538
  • [45] Significance of Measurable Residual Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia
    Gang, Margery
    Othus, Megan
    Walter, Roland B.
    CELLS, 2025, 14 (04)
  • [46] Clonal hematopoiesis and measurable residual disease assessment in acute myeloid leukemia
    Hasserjian, Robert P.
    Steensma, David P.
    Graubert, Timothy A.
    Ebert, Benjamin L.
    BLOOD, 2020, 135 (20) : 1729 - 1738
  • [47] Measurable Residual Disease in High-Risk Acute Myeloid Leukemia
    Cluzeau, Thomas
    Lemoli, Roberto M.
    McCloskey, James
    Cooper, Todd
    CANCERS, 2022, 14 (05)
  • [48] The present and future of measurable residual disease testing in acute myeloid leukemia
    Blachly, James S.
    Walter, Roland B.
    Hourigan, Christopher S.
    HAEMATOLOGICA, 2022, 107 (12) : 2810 - 2822
  • [49] Measurable residual disease testing for personalized treatment of acute myeloid leukemia
    Ehinger, Mats
    Pettersson, Louise
    APMIS, 2019, 127 (05) : 337 - 351
  • [50] Delving the depths of measurable residual disease negativity in acute myeloid leukemia
    Freeman, Sylvie D.
    HAEMATOLOGICA, 2022, 107 (12) : 2776 - 2778
12345